![]() This position is within Early-Stage Formulation Sciences responsible for designing and developing formulations and drug product presentations for Phase 1 through pivotal clinical trials. This is where you’ll find newly-designed, activity-based work spaces to suit a variety of working styles while increasing collaboration between teams. This includes a fitness center, employee healthcare clinic, electric vehicle charging stations, dry cleaning, full-service cafeteria and copy center. ![]() The Gaithersburg site offers a variety of amenities to help boost productivity and help keep our employees happy and healthy. We are dedicated to creating a culture of inclusion and collaboration. We believe employees benefit from being challenged and inspired at work. Here, we play host to some of the most cutting-edge technology and lab spaces, all designed to inspire collaboration and cross-functional science. This modern and vibrant scientific campus is the home of R&D and Oncology in the US. This campus employs more than 3,500 experts in our field and is only a short drive from Washington, DC. Our Gaithersburg, Maryland facility creates life-changing medicines for people around the world. If you are swift to action, confident to lead, willing to collaborate, and curious about what science can do, then you’re our kind of person. Working here means being entrepreneurial, thinking big and working together to make the impossible a reality. RedChip Companies, Strategic Advisors, Inc.Do you have a passion for Science? Would you like to apply your expertise to impact a company that follows the science and turns ideas into life changing medicines? Then AstraZeneca might be the one for you!Īt AstraZeneca, we put patients first and strive to meet their unmet needs worldwide. We are not obligated to publicly update or revise any forward-looking statement, whetherĪs a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actualĮvents and results may differ materially and are subject to risks, uncertainties, and assumptions about us. These and other factors may cause our actual results to differ materially from any forward-looking statement. InĮvaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company our ability to keep pace with new technology andĬhanging market needs and the competitive environment of our business. "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. ![]() You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections our growth in revenue andĮarnings and our business prospects and opportunities. We base these forward-looking statements on our expectations and projections about future events, which we derive from the informationĬurrently available to us. This press release contains forward-looking statements. BullFrog AI is deploying bfLEAP for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development,ĭecreasing the overall development costs by decreasing failure rates for new therapeutics.įor more information visit BullFrog AI at: Through its collaborations with leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAPĪrtificial intelligence platform. Listeners can sign up hereīullFrog AI is a technology-enabled drug development company that creates and analyzes networks of biological clinical and real-world data spanning from early discovery to late-stage clinical The two-day event is limited to members of M-VEST. Presenter: Vin Singh, Founder and CEO, BullFrog AI
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |